Early and Periodic Screening, Diagnosis and Treatment. Provider Orientation Packet

Transcription

1 Early and Periodic Screening, Diagnosis and Treatment Provider Orientation Packet

2 EPSDT Provider Orientation Packet Table of Contents Frequently Asked Questions and EPSDT Department Responsibilities... 3 Important Telephone Numbers... 4 EPSDT Components... 5 EPSDT Periodicity Schedule EPSDT Reporting/Billing EPSDT Referral Process... 9 EPSDT Eligibility Confirmation Fax Transmittal Sheet EPSDT Medical Record Review Requirements EPSDT Expanded Services EPSDT Screenings Recommended Immunizations from the CDC and Department of Health & Human Services Body Mass Index Charts from the CDC Referral Form (please complete EPSDT box)

3 Frequently Asked Questions Q: What is Early and Periodic Screening, Diagnosis and Treatment (EPSDT)? A: EPSDT is a Federally mandated program for Medicaid-eligible children ages birth to 21 years, which began in EPSDT uses a Periodicity Schedule based on the AAP/ Bright Futures Standards of Care and State guidelines. Q: Who do I contact with billing or other questions/concerns about the EPSDT program? A: Please contact your Provider Relations Specialist or Provider Services at (800) Q: What are the timely filing requirements for EPSDT? A: Providers must file within 180 days from the original date of service. This is consistent with Passport s policy for all claims. Q: Am I allowed to file sick and EPSDT visits for the same date of service? A: Yes, providers may file sick and EPSDT visits for the same date of service. Please follow standard coding guidelines for reporting the sick visit in addition to the EPSDT service. Q: How can I verify if a member is eligible for EPSDT? A: To verify EPSDT eligibility for four (4) or fewer members, call the EPSDT team at (877) ext and leave a message. You will receive a response within one hour during regular business hours. To confirm EPSDT eligibility for five (5) or more members, please complete the EPSDT Eligibility Confirmation Fax Transmittal Sheet (available on page 10) and fax to the EPSDT team at (502) at least 24 hours in advance. You will receive a faxed response within 24 hours. Q: How do determine the interval screenings for EPSDT? A: Please go to Passport s website and click on EPSDT for the Interval Screening Calculator. Q: How do I request outreach for non-compliant EPSDT members? A: Passport asks the provider office to attempt outreach to a member three times (i.e. phone calls, letters, and/or postcards) prior to contacting Passport for outreach. If these efforts have failed, please contact the EPSDT team at (877) ext to schedule member outreach. The requesting provider will receive notification regarding the outcome of the home visit within 60 days of the outreach request. EPSDT Department Responsibilities Passport is committed to working with our provider partners to improve the health and quality of life of our youngest members by using a comprehensive, integrated approach to care. Passport s EPSDT staff receive system notifications when outreach is necessary and when members are non-compliant. Here are some of the ways we may assist you with continuity and coordination of care for our members: Provide telephonic member and parent/guardian outreach and education. Remove barriers to care by assisting with transportation, scheduling appointments, and referrals to social services and specialists. Confirm EPSDT eligibility for providers. Refer members for a home visit, at the PCP s request. 3

4 Important Telephone Numbers Care Coordination Manager... (502) EPSDT Outreach Outreach Representative... (502) Outreach Representative... (502) EPSDT Eligibility Line... (502) Other Passport Departments Provider Services... (800) Member Services... (800) Utilization Management... (800) Local Assistance Vaccines for Children Program... (502) Transportation Brokers BROKER COUNTIES PHONE NUMBER LKLP Community Action Council Adair, Allen, Barren, Bath, Boone, Boyd, Breathitt, Breckinridge, Butler, Campbell, Carroll, Carter, Clay, Edmonson, Elliott, Gallatin, Grant, Grayson, Green, Greenup, Hardin, Harlan, Hart, Jackson, Kenton, Knott, Larue, Lawrence, Lee, Leslie, Letcher, Logan, Marion, Meade, Menifee, Metcalfe, Morgan, Nelson, Owen, Owsley, Pendleton, Perry, Rowan, Simpson, Taylor, Warren, Wolfe Pennyrile Allied Community Services Caldwell, Christian, Crittenden, Hopkins, Livingston, Lyon, Muhlenberg, Todd, Trigg Audubon Area Community Services (GRITS) Rural Transit Enterprises (RTEC) Federated Transit Services of the Bluegrass (FTSB) Bluegrass Community Action Partnership (BGCAP) Ballard, Calloway, Carlisle, Daviess, Fulton, Graves, Hancock, Henderson, Hickman McLean, Marshall, McCracken, Ohio, Union, Webster Bell, Clinton, Cumberland, Knox, Laurel,McCreary, Monroe, Pulaski, Rockcastle, Russell, Wayne, Whitley Bourbon, Bullitt, Clark, Estill, Fayette, Harrison, Henry, Jefferson, Madison, Montgomery, Nicholas, Oldham, Powell, Shelby, Spencer, Trimble Anderson, Boyle, Casey, Franklin, Garrard, Jessamine, Lincoln, Mercer, Scott, Washington, Woodford Licking Valley Community Action Program (LVCAP) Sandy Valley Transportation Services Bracken, Fleming, Lewis, Mason, Robertson Floyd, Johnson, Magoffin, Martin, Pike

5 EPSDT Components Medical History Physical exam Height and weight Weight to height ratio, BMI Hearing screen Vision screen Dental screen Growth and Development Social Personal Language Motor skills Nutrition Labs Urinalysis Lead Hematocrit Hemoglobin Tuberculosis Anticipatory Guidance Seat belt use Tobacco use Alcohol/drug abuse Sexual activity / STI s Mental health Immunizations 2014 Immunization Schedules (Available on page 6 and 7) Health and Education Parents and Children Teens 5

6 EPSDT Periodicity Schedule Recommendations for Preventive Pediatric Health Care Bright Futures/American Academy of Pediatrics The recommendations in this statement do not indicate an exclusive course of treatm standard of medical care. Variations, taking into account individual circumstances, m appropriate. Copyright 2014 by the American Academy of Pediatrics. No part of this statement may be reproduced in any form or by any means without p permission from the American Academy of Pediatrics except for one copy for persona These guidelines represent a consensus by the American Academy of Pediatrics (AAP) and Bright Futures.The AAP continues to emphasize the great importance of continuity of care in comprehensive health supervision and the need to avoid fragmentationof care. Refer to the specific guidance by age as listed in Bright Futures guidelines (Hagan JF, Shaw JS, Duncan PM, eds. Bright Futures Guidelines for Health Supervision of Infants, Children and Adolescents. 3 rd ed. Elk Grove Village, IL: American Academy of Pediatrics; 2008). child and family is unique; therefore,these Recommendationsfor Preventive PediatricHealth Care are gned for the care of children who are receiving competent parenting, have no manifestations of any rtant healthproblems, and are growing anddeveloping in satisfactory fashion.additionalvisits may ome necessary if circumstances suggest variations from normal. evelopmental, psychosocial, and chronic disease issues for children and adolescents may require ent counseling and treatment visits separatefrom preventive care visits. INFANCY EARLY CHILDHOOD MIDDLE CHILDHOOD ADOLESCENCE AGE 1 Prenatal 2 Newborn d 4 By 1 mo 2 mo 4 mo 6 mo 9 mo 12 mo 15 mo 18 mo 24 mo 30 mo 3 y 4 y 5 y 6 y 7 y 8 y 9 y 10 y 11 y 12 y 13 y 14 y 15 y 16 y 17 y 18 y 19 y 20 y HISTORY Initial/Interval MEASUREMENTS Length/Height and Weight Head Circumference Weight for Length Body Mass Index 5 Blood Pressure 6 SENSORY SCREENING Vision 7 Hearing 8 DEVELOPMENTAL/BEHAVIORAL ASSESSMENT Developmental Screening 9 Autism Screening 10 Developmental Surveillance Psychosocial/Behavioral Assessment Alcohol and Drug Use Assessment 11 Depression Screening 12 PHYSICAL EXAMINATION 13 PROCEDURES 14 Newborn Blood Screening 15 Critical Congenital Heart Defect Screening 16 Immunization 17 Hematocrit or Hemoglobin 18 Lead Screening 19 or 20 or 20 Tuberculosis Testing 21 6 Dyslipidemia Screening 22 STI/HIV Screening 23 Cervical Dysplasia Screening 24 ORAL HEALTH 25 or or or or ANTICIPATORY GUIDANCE 20. Perform risk assessments or screenings as appropriate, based on universal screening requirements for patients with Medicaid or in high prevalence areas. 21. Tuberculosis testing per recommendations of the Committee on Infectious Diseases, published in the current edition of AAP Red Book: Report of the Committee on Infectious Diseases. Testing should be performed on recognition of high-risk factors. 22. See AAP-endorsed 2011 guidelines from the National Heart Blood and Lung Institute, Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents ( 23. Adolescents should be screened for sexually transmitted infections (STIs) per recommendations in the current edition of the AAP Red Book: Report of the Committee on Infectious Diseases. Additionally, all adolescents should be screened for HIV according to the AAP statement ( once between the ages of 16 and 18, making every effort to preserve confidentiality of the adolescent. Those at increased risk of HIV infection, including those who are sexually active, participate in injection drug use, or are being tested for other STIs, should be tested for HIV and reassessed annually. 24. See USPSTF recommendations ( Indications for pelvic examinations prior to age 21 are noted in the 2010 AAP statement Gynecologic Examination for Adolescents in the Pediatric Office Setting ( 25. Refer to a dental home, if available. If not available, perform a risk assessment ( If primary water source is deficient in fluoride, consider oral fluoride supplementation. For those at high risk, consider application of fluoride varnish for caries prevention. See 2008 AAP statement Preventive Oral Health Intervention for Pediatricians ( and 2009 AAP statement Oral Health Risk Assessment Timing and Establishment of the Dental Home ( 11. A recommended screening tool is available at Recommended screening using the Patient Health Questionnaire (PHQ)-2 or other tools available in the GLAD-PC toolkit and at At each visit, age-appropriate physical examination is essential, with infant totally unclothed and older children undressed and suitably draped. See 2011 AAP statement Use of Chaperones During the Physical Examination of the Pediatric Patient ( 14. These may be modified, depending on entry point into schedule and individual need. 15. The Recommended Uniform Newborn Screening Panel ( as determined by The Secretary s Advisory Committee on Heritable Disorders in Newborns and Children, and state newborn screening laws/regulations ( establish the criteria for and coverage of newborn screening procedures and programs. Follow-up must be provided, as appropriate, by the pediatrician. 16. Screening for critical congenital heart disease using pulse oximetry should be performed in newborns, after 24 hours of age, before discharge from the hospital, per the 2011 AAP statement Endorsement of Health and Human Services Recommendation for Pulse Oximetry Screening for Critical Congenital Heart Disease ( 17. Schedules, per the AAP Committee on Infectious Diseases, are available at: Every visit should be an opportunity to update and complete a child s immunizations. 18. See 2010 AAP statement Diagnosis and Prevention of Iron Deficiency and Iron Deficiency Anemia in Infants and Young Children (0-3 Years of Age) ( 19. For children at risk of lead exposure, see the 2012 CDC Advisory Committee on Childhood Lead Poisoning Prevention statement Low Level Lead Exposure Harms Children: A Renewed Call for Primary Prevention ( 1. If a child comes under care for the first time at any point on the schedule, or if any items are not accomplished at the suggested age, the schedule should be brought up to date at the earliest possible time. 2. A prenatal visit is recommended for parents who are at high risk, for first-time parents, and for those who request a conference. The prenatal visit should include anticipatory guidance, pertinent medical history, and a discussion of benefits of breastfeeding and planned method of feeding, per the 2009 AAP statement The Prenatal Visit ( 3. Every infant should have a newborn evaluation after birth, and breastfeeding should be encouraged (and instruction and support should be offered). 4. Every infant should have an evaluation within 3 to 5 days of birth and within 48 to 72 hours after discharge from the hospital to include evaluation for feeding and jaundice. Breastfeeding infants should receive formal breastfeeding evaluation, and their mothers should receive encouragement and instruction, as recommended in the 2012 AAP statement Breastfeeding and the Use of Human Milk ( Newborn infants discharged less than 48 hours after delivery must be examined within 48 hours of discharge, per the 2010 AAP statement Hospital Stay for Healthy Term Newborns ( 5. Screen, per the 2007 AAP statement Expert Committee Recommendations Regarding the Prevention, Assessment, and Treatment of Child and Adolescent Overweight and Obesity: Summary Report ( 6. Blood pressure measurement in infants and children with specific risk conditions should be performed at visits before age 3 years. 7. If the patient is uncooperative, rescreen within 6 months, per the 2007 AAP statement Eye Examination in Infants, Children, and Young Adults by Pediatricians ( 8. All newborns should be screened, per the AAP statement Year 2007 Position Statement: Principles and Guidelines for Early Hearing Detection and Intervention Programs ( 9. See 2006 AAP statement Identifying Infants and Young Children With Developmental Disorders in the Medical Home: An Algorithm for Developmental Surveillance and Screening ( 10. Screening should occur per the 2007 AAP statement Identification and Evaluation of Children with Autism Spectrum Disorders ( KEY = to be performed = risk assessment to be performed with appropriate action to follow, if positive = range during which a service may be provided

7 Summary of changes made to the 2014 Bright Futures/AAP Recommendations for Preventive Pediatric Health Care (Periodicity Schedule) Changes to Developmental/Behavioral Assessment Alcohol and Drug Use Assessment- Information regarding a recommended screening tool (CRAFFT) was added. Depression- Screening for depression at ages 11 through 21 has been added, along with suggested screening tools. Changes to Procedures Dyslipidemia screening- An additional screening between 9 and 11 years of age has been added. The reference has been updated to the AAP-endorsed National Heart Blood and Lung Institute policy ( Hematocrit or hemoglobin- A risk assessment has been added at 15 and 30 months. The reference has been updated to the current AAP policy ( STI/HIV screening- A screen for HIV has been added between 16 and 18 years. Information on screening adolescents for HIV has been added in the footnotes. STI screening now references recommendations made in the AAP Red Book. This category was previously titled STI Screening. Cervical dysplasia- Adolescents should no longer be routinely screened for cervical dysplasia until age 21. Indications for pelvic exams prior to age 21 are noted in the 2010 AAP statement Gynecologic Examination for Adolescents in the Pediatric Office Setting ( Critical Congenital Heart Disease- Screening for critical congenital heart disease using pulse oximetry should be performed in newborns, after 24 hours of age, before discharge from the hospital, per the 2011 AAP statement, Endorsement of Health and Human Services Recommendation for Pulse Oximetry Screening for Critical Congenital Heart Disease ( For several recommendations, the AAP Policy has been updated since 2007 but there have been no changes in the timing of recommendations on the Periodicity Schedule. These include: Footnote 2- The Prenatal Visit (2009): Footnote 4- Breastfeeding and the Use of Human Milk (2012): and Hospital Stay for Healthy Term Newborns (2010): Footnote 8- Year 2007 Position Statement: Principles and Guidelines for Early Hearing Detection and Intervention Programs (2007): Footnote 10- Identification and Evaluation of Children with Autism Spectrum Disorders (2007): Footnote 17- Immunization Schedules (2014): and Footnote 19- CDC Advisory Committee on Childhood Lead Poisoning Prevention statement Low Level Lead Exposure Harms Children: A Renewed Call for Primary Prevention (2012): Footnote 22- AAP-endorsed guideline Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents (2011): Footnote 25- Preventive Oral Health Intervention for Pediatricians (2008): and Oral Health Risk Assessment Timing and Establishment of the Dental Home (2009): Additional information from the policies regarding fluoride supplementation and fluoride varnish has been added to the footnote. New references were added for several footnotes, also with no change to recommendations in the Periodicity Schedule: Footnote 5- Expert Committee Recommendations Regarding the Prevention, Assessment, and Treatment of Child and Adolescent Overweight and Obesity: Summary Report (2007): Footnote 13- Use of Chaperones During the Physical Examination of the Pediatric Patient (2011): Footnote 15- The Recommended Uniform Newborn Screening Panel ( mmendedpanel/uniformscreeningpanel.pdf), as determined by The Secretary s Advisory Committee on Heritable Disorders in Newborns and Children, and state newborn screening laws/regulations ( establish the criteria for and coverage of newborn screening procedures and programs. Follow-up must be provided, as appropriate, by the pediatrician. For consistency, the title of Tuberculin Test has been changed to Tuberculosis Testing. The title of Newborn Metabolic/Hemoglobin Screening has been changed to Newborn Blood Screening. 7

8 EPSDT Reporting/Billing Billing for EPSDT Services All EPSDT services must be submitted as part of the standard electronic (837) or paper (CMS-1500) claims submission process. Steps for Billing EPSDT Services To submit EPSDT services via claims you must: 1. Continue to bill using the same codes for comprehensive history and physical exam you use today. These codes must correspond with the member s age New Patient Series Established Patient Series 2. Add an EP modifier to the physical exam code only when all components of the appropriate EPSDT screening interval have been completed and documented in the member s medical record. Do not add the EP modifier to other services being billed (i.e. immunizations). As a reminder, do not bill lab or testing components individually if they were conducted as part of an EPSDT screening interval. 3. Acknowledge the following health evaluation services have been completed by submitting the appropriate CPT Category II codes, according to the member s age, as outlined below. CPT II codes must include a nominal charge (i.e. $.01 or $1.00 not blank or zero) in order to adjudicate correctly. Member Age: CPT II Code: Description: Two (2) Years and Above 3008F To confirm the BMI has been performed and documented in the member s medical record. (Value and percentile must be recorded.) Nine (9) Years and Above 2014F To confirm the member s mental status has been assessed and documented in the member s medical record. NOTE: Failure to submit these codes as required above will result in denial of the EPSDT payment. 8

9 EPSDT Services Requiring Resubmission The EPSDT Screening Form will no longer be accepted by Passport for resubmission, regardless of the date of service. All EPSDT services requiring resubmission must be submitted to Passport via the billing process described above. Other Codes for Capturing Health Status Information The Plan encourages all providers to submit additional CPT Category II codes to describe and report other important health status information. Examples include: 1035F Current Smokeless Tobacco User 1039F Intermittent Asthma 1000F Tobacco Use Assessed (CAD, CAP, COPD, PV, DM) 4004F Patient Screened for Tobacco Use and Received Tobacco Cessation Counseling (if identified as a tobacco user) Passport accepts all valid CPT Category II codes. These codes are for informational purposes only and do not qualify for reimbursement. However, these codes must be submitted with a nominal charge (i.e. $.01 or $1.00 not blank or zero) in order to adjudicate correctly. Codes will display as denied on the remittance advice with a description stating non-covered services. EPSDT Referral Process The Department for Medicaid Services (DMS) has requested that Passport provide new statistics related to the EPSDT program that we aid in administering for the region. Specifically, Passport must conduct and demonstrate follow-up to members, and refer providers and consultants to ensure that members receive medically necessary evaluation, diagnostics, and/or treatment as a result of referrals related to EPSDT screenings. Effective February 1, 2013, PCPs are required to denote whether a referral to a specialist was issued as a result of an ageappropriate EPSDT screen. When entering a referral in Navinet, please indicate by checking the EPSDT box if referral is due to EPSDT. 9

10 Passport Health Plan 5100 Commerce Crossings Drive Louisville, KY Phone: Fax: FAX TRANSMITTAL Confirmation of eligibility is not a guarantee of payment. To: EPSDT Team From: Fax: Page(s): Phone: Date: Re: EPSDT Eligibility Confirmation CC: To confirm EPSDT eligibility on five (5) or more members, please fax your request to the EPSDT Team at , at least 24 hours in advance. Otherwise, please leave a message on the EPSDT Team Voic at Passport Health Plan Member I.D. # Name D.O.B. D.O.S. Eligibility Days for this Screen Passport Use Only Yes No Reason Confidentiality notice: This fax is intended for the sole use of the individual and entity to whom it is addressed and may contain information that is confidential and exempt from disclosure under applicable law. If you are not the intended addressee nor authorized to receive this fax for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute to anyone the message or any information contained in the message to anyone. If you have received this fax in error, please immediately advise the sender at the phone number listed at the top of the page and shred the fax. Thank you very much Passport Health Plan RR

11 EPSDT Medical Record Review Requirements To ensure all EPSDT components are being performed, services must be documented in members chart. Key areas of focus are: History & physical exam - Height & weight - Height to weight ratio BMI (Value & percentile must be plotted for members under the age of 16 years of age, available on pages 24 and 25. Hearing Screening Vision screening Labs (including lead screen) Mental health assessment (ages 9 and above) Anticipatory guidance Dental referral Immunizations up to date These items are based on Passport s/aap s periodicity schedule EPSDT Expanded Services EPSDT Expanded Services are those services required to treat conditions detected during an encounter with a health care professional and eligible for payment under the Federal Medicaid program but not currently recognized under the State plan. All Passport members under the age of 21 are also eligible for EPSDT Expanded Services when such services are determined to be medically necessary. There is no limitation on the length of approval for these services so long as the conditions for medical necessity continue to be met and the member remains eligible for Passport benefits. Prior Authorization Process for EPSDT Expanded Services Providers must forward all requests for EPSDT Expanded Services to the Passport Utilization Management (UM) department for medical necessity review. Providers must also attach a letter of medical necessity outlining the rationale for the request and the benefit that requested service(s) will yield for the member. Although Utilization Management will accept letters of medical necessity from either a member s PCP, a participating specialist or ancillary provider, the PCP will be asked to approve the treatment plan if he/she was not involved in the initial request to ensure continuity of care. EPSDT Expanded / Special Services: 1. EPSDT Expanded / Special Services are available only to individuals under age 21. Services may be provided through the last day of the month in which the individual turns 21. For example, if someone is receiving services through the EPSDT Special Services Program, and their 21st birthday is March 16, they may continue to receive services through EPSDT Special Services through March 31 (if they are still eligible for Medicaid.) 2. EPSDT Special Services does not cover: a. Respite care, environmental, educational, vocational, cosmetic, convenience, experimental, and over the counter items. 3. Examples of a service covered under EPSDT: a. Additional pairs of eyeglasses after the Medicaid Vision Program has paid for the first two pair in a year. b. Additional dental cleanings after the Medicaid Dental Program has paid for one cleaning. 11

12 c. Nutritional products when they are used as a supplement rather than as the child s total nutrition. d. Speech therapy, occupational therapy or physical therapy when the therapy does not meet the criteria for the Medicaid Home Health Program. e. Private Duty Nursing beyond the 2,000 hour per year limit. 4. All EPSDT Special Services require a review for medical necessity by the appropriate entity (i.e., Block for vision services). 5. If a service is covered under Medicaid then the service would not be considered EPSDT and would fall under the member s regular Passport coverage. EPSDT Screenings EPSDT Screenings include these areas of health in which the PCP must check for members ages birth to 21 years: Medical history and physical exams Dental screens Vision screens Lab tests including blood lead level Hearing screens Immunizations (shots) Nutrition Growth and development check: (social, personal, Mental health, substance abuse assessments language, and motor skills) and other age appropriate counseling Body Mass Index (BMI) Members should have an EPSDT Screening at the following ages: Infancy Early Childhood Middle Childhood Adolescence Birth to 1 month 15 months 5 years 11 years 2 months 18 months 6 years 12 years 4 months 24 months 7 years 13 years 6 months 30 months 8 years 14 years 9 months 3 years 9 years 15 years 12 months 4 years 10 years 16 years 17 years 18 years 19 years 20 years 12

13 Recommended Immunization Schedules for Persons Aged 0 Through 18 Years UNITED STATES, 2014 This schedule includes recommendations in effect as of January 1, Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. The use of a combination vaccine generally is preferred over separate injections of its equivalent component vaccines. Vaccination providers should consult the relevant Advisory Committee on Immunization Practices (ACIP) statement for detailed recommendations, available online at Clinically significant adverse events that follow vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS) online ( or by telephone ( ). The Recommended Immunization Schedules for Persons Aged 0 Through 18 Years are approved by the Advisory Committee on Immunization Practices ( American Academy of Pediatrics ( American Academy of Family Physicians ( American College of Obstetricians and Gynecologists ( U.S. Department of Health and Human Services Centers for Disease Control and Prevention 13

14 Figure 1. Recommended immunization schedule for persons aged 0 through 18 years United States, (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in Figure 1. To determine minimum intervals between doses, see the catch-up schedule (Figure 2). School entry and adolescent vaccine age groups are in bold. Vaccine Birth 1 mo 2 mos 4 mos 6 mos 9 mos 12 mos 15 mos 18 mos mos 2-3 yrs 4-6 yrs 7-10 yrs yrs yrs yrs Hepatitis B 1 (HepB) 1 st dose 2 nd dose 3 rd dose Rotavirus 2 (RV) RV1 (2-dose series); RV5 (3-dose series) Diphtheria, tetanus, & acellular pertussis 3 (DTaP: <7 yrs) Tetanus, diphtheria, & acellular pertussis 4 (Tdap: >7 yrs) Haemophilus influenzae type b 5 (Hib) Pneumococcal conjugate 6 (PCV13) Pneumococcal polysaccharide 6 (PPSV23) Inactivated poliovirus 7 (IPV) (<18 yrs) Influenza 8 (IIV; LAIV) 2 doses for some: See footnote 8 Measles, mumps, rubella 9 (MMR) 1 st dose 1 st dose 1 st dose 1 st dose 1 st dose 2 nd dose 2 nd dose 2 nd dose 2 nd dose 2 nd dose See footnote 2 3 rd dose See footnote 5 3 rd dose 3 rd or 4 th dose, See footnote 5 3 rd dose 4 th dose 1 st dose 4 th dose Annual vaccination (IIV only) 5 th dose 4 th dose 2 nd dose (Tdap) Annual vaccination (IIV or LAIV) Varicella 10 (VAR) 1 st dose 2 nd dose Hepatitis A 11 (HepA) 2-dose series, See footnote 11 Human papillomavirus 12 (HPV2: females only; HPV4: males and females) Meningococcal 13 (Hib-Men- CY > 6 weeks; MenACWY-D >9 mos; MenACWY-CRM 2 mos) See footnote 13 (3-dose series) 1 st dose Booster Range of recommended ages for all children Range of recommended ages for catch-up immunization Range of recommended ages for certain high-risk groups Range of recommended ages during which catch-up is encouraged and for certain high-risk groups Not routinely recommended This schedule includes recommendations in effect as of January 1, Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. The use of a combination vaccine generally is preferred over separate injections of its equivalent component vaccines. Vaccination providers should consult the relevant Advisory Committee on Immunization Practices (ACIP) statement for detailed recommendations, available online at Clinically significant adverse events that follow vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS) online ( or by telephone ( ).Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. Additional information, including precautions and contraindications for vaccination, is available from CDC online ( or by telephone (800-CDC-INFO [ ]). This schedule is approved by the Advisory Committee on Immunization Practices (http// the American Academy of Pediatrics ( the American Academy of Family Physicians ( and the American College of Obstetricians and Gynecologists ( NOTE: The above recommendations must be read along with the footnotes of this schedule. 14

15 FIGURE 2. Catch-up immunization schedule for persons aged 4 months through 18 years who start late or who are more than 1 month behind United States, The figure below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child s age. Always use this table in conjunction with Figure 1 and the footnotes that follow. Persons aged 4 months through 6 years Vaccine Minimum Age for Dose 1 Minimum Interval Between Doses Dose 1 to dose 2 Dose 2 to dose 3 Dose 3 to dose 4 Dose 4 to dose 5 Hepatitis B 1 Birth 4 weeks 8 weeks and at least 16 weeks after first dose; minimum age for the final dose is 24 weeks Rotavirus 2 6 weeks 4 weeks 4 weeks 2 Diphtheria, tetanus, & acellular pertussis 3 6 weeks 4 weeks 4 weeks 6 months 6 months 3 Haemophilus influenzae type b 5 6 weeks 4 weeks if first dose administered at younger than age 12 months 8 weeks (as final dose) if first dose administered at age 12 through 14 months No further doses needed if first dose administered at age 15 months or older 4 weeks 5 if current age is younger than 12 months and first dose administered at < 7 months old 8 weeks and age 12 months through 59 months (as final dose) 5 if current age is younger than 12 months and first dose administered between 7 through 11 months (regardless of Hib vaccine [PRP-T or PRP-OMP] used for first dose); OR if current age is 12 through 59 months and first dose administered at younger than age 12 months; OR first 2 doses were PRP-OMP and administered at younger than 12 months. No further doses needed if previous dose administered at age 15 months or older 8 weeks (as final dose) This dose only necessary for children aged 12 through 59 months who received 3 (PRP-T) doses before age 12 months and started the primary series before age 7 months Pneumococcal 6 6 weeks 4 weeks if first dose administered at younger than age 12 months 8 weeks (as final dose for healthy children) if first dose administered at age 12 months or older No further doses needed for healthy children if first dose administered at age 24 months or older 4 weeks if current age is younger than 12 months 8 weeks (as final dose for healthy children) if current age is 12 months or older No further doses needed for healthy children if previous dose administered at age 24 months or older 8 weeks (as final dose) This dose only necessary for children aged 12 through 59 months who received 3 doses before age 12 months or for children at high risk who received 3 doses at any age Inactivated poliovirus 7 6 weeks 4 weeks 7 4 weeks 7 6 months 7 minimum age 4 years for final dose Meningococcal 13 6 weeks 8 weeks 13 See footnote 13 See footnote 13 Measles, mumps, 12 rubella 9 months 4 weeks Varicella months 3 months Hepatitis A months 6 months Persons aged 7 through 18 years Tetanus, diphtheria; tetanus, diphtheria, & 7 years 4 4 weeks acellular pertussis 4 4 weeks if first dose of DTaP/DT administered at younger than age 12 months 6 months if first dose of DTaP/DT administered at age 12 months or older and then no further doses needed for catch-up 6 months if first dose of DTaP/DT administered at younger than age 12 months Human papillomavirus 12 9 years Routine dosing intervals are recommended 12 Hepatitis A months 6 months Hepatitis B 1 Birth 4 weeks 8 weeks (and at least 16 weeks after first dose) Inactivated poliovirus 7 6 weeks 4 weeks 4 weeks 7 6 months 7 Meningococcal 13 6 weeks 8 weeks 13 Measles, mumps, rubella 9 12 months 4 weeks Varicella months 3 months if person is younger than age 13 years 4 weeks if person is aged 13 years or older NOTE: The above recommendations must be read along with the footnotes of this schedule. 15

16 Footnotes Recommended immunization schedule for persons aged 0 through 18 years United States, 2014 For further guidance on the use of the vaccines mentioned below, see: For vaccine recommendations for persons 19 years of age and older, see the adult immunization schedule. Additional information For contraindications and precautions to use of a vaccine and for additional information regarding that vaccine, vaccination providers should consult the relevant ACIP statement available online at For purposes of calculating intervals between doses, 4 weeks = 28 days. Intervals of 4 months or greater are determined by calendar months. Vaccine doses administered 4 days or less before the minimum interval are considered valid. Doses of any vaccine administered 5 days earlier than the minimum interval or minimum age should not be counted as valid doses and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see MMWR, General Recommendations on Immunization and Reports / Vol. 60 / No. 2; Table 1. Recommended and minimum ages and intervals between vaccine doses available online at Information on travel vaccine requirements and recommendations is available at For vaccination of persons with primary and secondary immunodeficiencies, see Table 13, Vaccination of persons with primary and secondary immunodeficiencies, in General Recommendations on Immunization (ACIP), available at and American Academy of Pediatrics. Immunization in Special Clinical Circumstances, in Pickering LK, Baker CJ, Kimberlin DW, Long SS eds. Red Book: 2012 report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics. 1. Hepatitis B (HepB) vaccine. (Minimum age: birth) Routine vaccination: At birth: Administer monovalent HepB vaccine to all newborns before hospital discharge. For infants born to hepatitis B surface antigen (HBsAg)-positive mothers, administer HepB vaccine and 0.5 ml of hepatitis B immune globulin (HBIG) within 12 hours of birth. These infants should be tested for HBsAg and antibody to HBsAg (anti-hbs) 1 to 2 months after completion of the HepB series, at age 9 through 18 months (preferably at the next well-child visit). If mother s HBsAg status is unknown, within 12 hours of birth administer HepB vaccine regardless of birth weight. For infants weighing less than 2,000 grams, administer HBIG in addition to HepB vaccine within 12 hours of birth. Determine mother s HBsAg status as soon as possible and, if mother is HBsAgpositive, also administer HBIG for infants weighing 2,000 grams or more as soon as possible, but no later than age 7 days. Doses following the birth dose: The second dose should be administered at age 1 or 2 months. Monovalent HepB vaccine should be used for doses administered before age 6 weeks. Infants who did not receive a birth dose should receive 3 doses of a HepB-containing vaccine on a schedule of 0, 1 to 2 months, and 6 months starting as soon as feasible. See Figure 2. Administer the second dose 1 to 2 months after the first dose (minimum interval of 4 weeks), administer the third dose at least 8 weeks after the second dose AND at least 16 weeks after the first dose. The final (third or fourth) dose in the HepB vaccine series should be administered no earlier than age 24 weeks. Administration of a total of 4 doses of HepB vaccine is permitted when a combination vaccine containing HepB is administered after the birth dose. Catch-up vaccination: Unvaccinated persons should complete a 3-dose series. A 2-dose series (doses separated by at least 4 months) of adult formulation Recombivax HB is licensed for use in children aged 11 through 15 years. For other catch-up guidance, see Figure Rotavirus (RV) vaccines. (Minimum age: 6 weeks for both RV1 [Rotarix] and RV5 [RotaTeq]) Routine vaccination: Administer a series of RV vaccine to all infants as follows: 1. If Rotarix is used, administer a 2-dose series at 2 and 4 months of age. 2. If RotaTeq is used, administer a 3-dose series at ages 2, 4, and 6 months. 3. If any dose in the series was RotaTeq or vaccine product is unknown for any dose in the series, a total of 3 doses of RV vaccine should be administered. Catch-up vaccination: The maximum age for the first dose in the series is 14 weeks, 6 days; vaccination should not be initiated for infants aged 15 weeks, 0 days or older. The maximum age for the final dose in the series is 8 months, 0 days. For other catch-up guidance, see Figure Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. (Minimum age: 6 weeks. Exception: DTaP-IPV [Kinrix]: 4 years) Routine vaccination: Administer a 5-dose series of DTaP vaccine at ages 2, 4, 6, 15 through 18 months, and 4 through 6 years. The fourth dose may be administered as early as age 12 months, provided at least 6 months have elapsed since the third dose. Catch-up vaccination: The fifth dose of DTaP vaccine is not necessary if the fourth dose was administered at age 4 years or older. For other catch-up guidance, see Figure Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine. (Minimum age: 10 years for Boostrix, 11 years for Adacel) Routine vaccination: Administer 1 dose of Tdap vaccine to all adolescents aged 11 through 12 years. Tdap may be administered regardless of the interval since the last tetanus and diphtheria toxoid-containing vaccine. Administer 1 dose of Tdap vaccine to pregnant adolescents during each pregnancy (preferred during 27 through 36 weeks gestation) regardless of time since prior Td or Tdap vaccination. Catch-up vaccination: Persons aged 7 years and older who are not fully immunized with DTaP vaccine should receive Tdap vaccine as 1 (preferably the first) dose in the catch-up series; if additional doses are needed, use Td vaccine. For children 7 through 10 years who receive a dose of Tdap as part of the catch-up series, an adolescent Tdap vaccine dose at age 11 through 12 years should NOT be administered. Td should be administered instead 10 years after the Tdap dose. Persons aged 11 through 18 years who have not received Tdap vaccine should receive a dose followed by tetanus and diphtheria toxoids (Td) booster doses every 10 years thereafter. Inadvertent doses of DTaP vaccine: - If administered inadvertently to a child aged 7 through 10 years may count as part of the catch-up series. This dose may count as the adolescent Tdap dose, or the child can later receive a Tdap booster dose at age 11 through 12 years. - If administered inadvertently to an adolescent aged 11 through 18 years, the dose should be counted as the adolescent Tdap booster. For other catch-up guidance, see Figure Haemophilus influenzae type b (Hib) conjugate vaccine. (Minimum age: 6 weeks for PRP-T [ACTHIB, DTaP-IPV/Hib (Pentacel) and Hib-MenCY (MenHibrix)], PRP-OMP [PedvaxHIB or COMVAX], 12 months for PRP-T [Hiberix]) Routine vaccination: Administer a 2- or 3-dose Hib vaccine primary series and a booster dose (dose 3 or 4 depending on vaccine used in primary series) at age 12 through 15 months to complete a full Hib vaccine series. The primary series with ActHIB, MenHibrix, or Pentacel consists of 3 doses and should be administered at 2, 4, and 6 months of age. The primary series with PedvaxHib or COMVAX consists of 2 doses and should be administered at 2 and 4 months of age; a dose at age 6 months is not indicated. One booster dose (dose 3 or 4 depending on vaccine used in primary series) of any Hib vaccine should be administered at age 12 through 15 months. An exception is Hiberix vaccine. Hiberix should only be used for the booster (final) dose in children aged 12 months through 4 years who have received at least 1 prior dose of Hib-containing vaccine. 16

17 For further guidance on the use of the vaccines mentioned below, see: 5. Haemophilus influenzae type b (Hib) conjugate vaccine (cont d) For recommendations on the use of MenHibrix in patients at increased risk for meningococcal disease, please refer to the meningococcal vaccine footnotes and also to MMWR March 22, 2013; 62(RR02);1-22, available at Catch-up vaccination: If dose 1 was administered at ages 12 through 14 months, administer a second (final) dose at least 8 weeks after dose 1, regardless of Hib vaccine used in the primary series. If the first 2 doses were PRP-OMP (PedvaxHIB or COMVAX), and were administered at age 11 months or younger, the third (and final) dose should be administered at age 12 through 15 months and at least 8 weeks after the second dose. If the first dose was administered at age 7 through 11 months, administer the second dose at least 4 weeks later and a third (and final) dose at age 12 through 15 months or 8 weeks after second dose, whichever is later, regardless of Hib vaccine used for first dose. If first dose is administered at younger than 12 months of age and second dose is given between 12 through 14 months of age, a third (and final) dose should be given 8 weeks later. For unvaccinated children aged 15 months or older, administer only 1 dose. For other catch-up guidance, see Figure 2. For catch-up guidance related to MenHibrix, please see the meningococcal vaccine footnotes and also MMWR March 22, 2013; 62(RR02);1-22, available at Vaccination of persons with high-risk conditions: Children aged 12 through 59 months who are at increased risk for Hib disease, including chemotherapy recipients and those with anatomic or functional asplenia (including sickle cell disease), human immunodeficiency virus (HIV) infection, immunoglobulin deficiency, or early component complement deficiency, who have received either no doses or only 1 dose of Hib vaccine before 12 months of age, should receive 2 additional doses of Hib vaccine 8 weeks apart; children who received 2 or more doses of Hib vaccine before 12 months of age should receive 1 additional dose. For patients younger than 5 years of age undergoing chemotherapy or radiation treatment who received a Hib vaccine dose(s) within 14 days of starting therapy or during therapy, repeat the dose(s) at least 3 months following therapy completion. Recipients of hematopoietic stem cell transplant (HSCT) should be revaccinated with a 3-dose regimen of Hib vaccine starting 6 to 12 months after successful transplant, regardless of vaccination history; doses should be administered at least 4 weeks apart. A single dose of any Hib-containing vaccine should be administered to unimmunized* children and adolescents 15 months of age and older undergoing an elective splenectomy; if possible, vaccine should be administered at least 14 days before procedure. Hib vaccine is not routinely recommended for patients 5 years or older. However, 1 dose of Hib vaccine should be administered to unimmunized* persons aged 5 years or older who have anatomic or functional asplenia (including sickle cell disease) and unvaccinated persons 5 through 18 years of age with human immunodeficiency virus (HIV) infection. * Patients who have not received a primary series and booster dose or at least 1 dose of Hib vaccine after 14 months of age are considered unimmunized. 6. Pneumococcal vaccines. (Minimum age: 6 weeks for PCV13, 2 years for PPSV23) Routine vaccination with PCV13: Administer a 4-dose series of PCV13 vaccine at ages 2, 4, and 6 months and at age 12 through 15 months. For children aged 14 through 59 months who have received an age-appropriate series of 7-valent PCV (PCV7), administer a single supplemental dose of 13-valent PCV (PCV13). Catch-up vaccination with PCV13: Administer 1 dose of PCV13 to all healthy children aged 24 through 59 months who are not completely vaccinated for their age. For other catch-up guidance, see Figure 2. Vaccination of persons with high-risk conditions with PCV13 and PPSV23: All recommended PCV13 doses should be administered prior to PPSV23 vaccination if possible. For children 2 through 5 years of age with any of the following conditions: chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma if treated with high-dose oral corticosteroid therapy); diabetes mellitus; cerebrospinal fluid leak; cochlear implant; sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin disease; solid organ transplantation; or congenital immunodeficiency: 1. Administer 1 dose of PCV13 if 3 doses of PCV (PCV7 and/or PCV13) were received previously. 2. Administer 2 doses of PCV13 at least 8 weeks apart if fewer than 3 doses of PCV (PCV7 and/or PCV13) were received previously. 6. Pneumococcal vaccines (cont d) 3. Administer 1 supplemental dose of PCV13 if 4 doses of PCV7 or other age-appropriate complete PCV7 series was received previously. 4. The minimum interval between doses of PCV (PCV7 or PCV13) is 8 weeks. 5. For children with no history of PPSV23 vaccination, administer PPSV23 at least 8 weeks after the most recent dose of PCV13. For children aged 6 through 18 years who have cerebrospinal fluid leak; cochlear implant; sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiencies; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin disease; generalized malignancy; solid organ transplantation; or multiple myeloma: 1. If neither PCV13 nor PPSV23 has been received previously, administer 1 dose of PCV13 now and 1 dose of PPSV23 at least 8 weeks later. 2. If PCV13 has been received previously but PPSV23 has not, administer 1 dose of PPSV23 at least 8 weeks after the most recent dose of PCV If PPSV23 has been received but PCV13 has not, administer 1 dose of PCV13 at least 8 weeks after the most recent dose of PPSV23. For children aged 6 through 18 years with chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure), chronic lung disease (including asthma if treated with high-dose oral corticosteroid therapy), diabetes mellitus, alcoholism, or chronic liver disease, who have not received PPSV23, administer 1 dose of PPSV23. If PCV13 has been received previously, then PPSV23 should be administered at least 8 weeks after any prior PCV13 dose. A single revaccination with PPSV23 should be administered 5 years after the first dose to children with sickle cell disease or other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiencies; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin disease; generalized malignancy; solid organ transplantation; or multiple myeloma. 7. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks) Routine vaccination: Administer a 4-dose series of IPV at ages 2, 4, 6 through 18 months, and 4 through 6 years. The final dose in the series should be administered on or after the fourth birthday and at least 6 months after the previous dose. Catch-up vaccination: In the first 6 months of life, minimum age and minimum intervals are only recommended if the person is at risk for imminent exposure to circulating poliovirus (i.e., travel to a polio-endemic region or during an outbreak). If 4 or more doses are administered before age 4 years, an additional dose should be administered at age 4 through 6 years and at least 6 months after the previous dose. A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose. If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child s current age. IPV is not routinely recommended for U.S. residents aged 18 years or older. For other catch-up guidance, see Figure Influenza vaccines. (Minimum age: 6 months for inactivated influenza vaccine [IIV], 2 years for live, attenuated influenza vaccine [LAIV]) Routine vaccination: Administer influenza vaccine annually to all children beginning at age 6 months. For most healthy, nonpregnant persons aged 2 through 49 years, either LAIV or IIV may be used. However, LAIV should NOT be administered to some persons, including 1) those with asthma, 2) children 2 through 4 years who had wheezing in the past 12 months, or 3) those who have any other underlying medical conditions that predispose them to influenza complications. For all other contraindications to use of LAIV, see MMWR 2013; 62 (No. RR-7):1-43, available at For children aged 6 months through 8 years: For the season, administer 2 doses (separated by at least 4 weeks) to children who are receiving influenza vaccine for the first time. Some children in this age group who have been vaccinated previously will also need 2 doses. For additional guidance, follow dosing guidelines in the ACIP influenza vaccine recommendations, MMWR 2013; 62 (No. RR-7):1-43, available at For the season, follow dosing guidelines in the 2014 ACIP influenza vaccine recommendations. For persons aged 9 years and older: Administer 1 dose. 17